| MDR | median duration of response; medical device reporting; minimum daily requirement; multidrug resistan... |
|---|---|
| MHR | major histocompatibility region; malignant hyperthermia resistance; maternal heart rate; maximal hea... |
| MR | Maddox rods; magnetic resistance; magnetic resonance; mandibular reflex; mannose-resistant; may repe... |
| MRP | mean resisting potential; medical reimbursement plan; multidrug resistance-associated protein |
| MVR | massive vitreous reaction; microvitreoretinal; minimal vascular resistance; mitral valve replacement... |
| drug industry | That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function. (12 Dec 1998) |
|---|---|
| drug information services | Services providing pharmaceutic and therapeutic drug information and consultation. (12 Dec 1998) |
| drug interaction | <pharmacology> A chemical or physiologic reaction that can occur when two different medications are taken together and the interaction may affect the metabolism, effectiveness or toxicity of the other. (18 Jul 2002) |
| drug labelling | Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information. (12 Dec 1998) |
| drug monitoring | The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. (12 Dec 1998) |
| drug, over-the-counter | Drug for which a prescription is not needed. (12 Dec 1998) |
| drug packaging | Containers, packaging, and packaging materials for drugs and biological products. These include those in ampule, capsule, tablet, solution or other forms. Packaging includes immediate-containers, secondary-containers, and cartons. In the united states, such packaging is controlled under the federal food, drug, and cosmetic act which also stipulates requirements for tamper-resistance and child-resistance. Similar laws govern use elsewhere. drug labeling is also available. (12 Dec 1998) |
| drug pathogenesis | The production of morbid symptoms by drugs. (05 Mar 2000) |
| drug, prescription | A drug requiring a prescription, a physician's order. By comparison with an over-the-counter drug. (12 Dec 1998) |
| drug psychosis | Psychosis following or precipitated by ingestion of a drug, e.g., LSD. (05 Mar 2000) |
| drug rash | Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. (12 Dec 1998) |
| drug residues | Drugs and their metabolites which are found in the edible tissues and milk of animals after their medication with specific drugs. This term can also apply to drugs found in adipose tissue of humans after drug treatment. (12 Dec 1998) |
| drug resistant | Unresponsive to the desired effects of drugs or other therapy for example: irradiation cytotoxic agents or hormones. Drug resistance of cells within tumours is probably the major cause of treatment failure. (16 Dec 1997) |
| drug screening | Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. (12 Dec 1998) |
| drug screening assays, antitumour | Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumour growth parameters in laboratory animals. (12 Dec 1998) |